Abemaciclib

• Description :

  Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

• Product Name Alternative :

  LY2835219

• UNSPSC :

  12352005

• Hazard Statement :

  H360, H373, H410

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/LY2835219-free-base.html

• Purity :

  99.97

• Solubility :

  DMSO : 2.94 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C

• Molecular Formula :

  C27H32F2N8

• Molecular Weight :

  506.59

• Precautions :

  H360, H373, H410

• References & Citations :

  [1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7 (12) :14803-13.|[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13 (10) :2253-63.|[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32 (5) :825-37.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

• Citation 01 :

  ACS Appl Mater Interfaces. 2022 May 11;14 (18) :20628-20640.|Acta Neuropathol Commun. 2025 Jun 28;13 (1) :143.|Adv Funct Mater. 2021 Apr 30.|Adv Sci (Weinh) . 2020 Aug 4;7 (18) :2000906.|Adv Sci (Weinh) . 2022 Aug 2; e2201834.|Anticancer Res. 2025 Jun;45 (6) :2285-2295.|Bioact Mater. 2021 Sep 8:10:247-254.|Biochem Biophys Res Commun. 2022 Jan 15:588:147-153.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Chromatogr. 2020 Jun;34 (6) :e4825.|Biomed Pharmacother. 2025 Aug:189:118340.|bioRxiv. 2023 Jan 25.|bioRxiv. 2023 Jul 17.|bioRxiv. 2023 Jul 19:2023.07.19.549715.|bioRxiv. 2024 Dec 10:2024.12.09.627542.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2025 Sep 15.|Blood Cancer J. 2022 Jan 11;12 (1) :5.|Br J Cancer. 2022 Jun;126 (11) :1616-1626.|Breast Cancer Res. 2019 Dec 26;21 (1) :150.|Cancer Cell. 2024 Aug 27:S1535-6108 (24) 00305-2.|Cancer Discov. 2024 Mar 1;14 (3) :446-467.|Cancer Gene Ther. 2025 Aug 14.|Cancer Res. 2017 May 1;77 (9) :2488-2499.|Cancer Res. 2019 Oct 15;79 (20) :5245-5259.|Cancer Res. 2022 May 16;82 (10) :1890-1908.|Cell Chem Biol. 2019 Aug 15;26 (8) :1067-1080.e8. |Cell Death Dis. 2020 Oct 28;11 (10) :925.|Cell Rep. 2022 Dec 20;41 (12) :111826.|Cell Rep. 2024 Dec 30;44 (1) :115116.|Cell. 2023 Jun 8;186 (12) :2628-2643.e21.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.|Commun Biol. 2021 Mar 25;4 (1) :399.|Dartmouth College. 2025.|Department of Biochemistry. 2020 Oct.|EMBO J. 2024 Dec;43 (23) :5972-6000.|EMBO J. 2024 Oct;43 (19) :4406-4436.|EMBO Mol Med. 2025 Aug 29.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Front Oncol. 2021 Jul 13:11:704042.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Heliyon. 2023 Sep 14;9 (9) :e19760.|Int J Biol Sci. 2019 Jan 1;15 (3) :522-532. |Int J Mol Med. 2025 Nov;56 (5) :167.|Int J Mol Sci. 2021 Jan 8;22 (2) :575.|Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|J Biol Chem. 2025 Jan 16:108196.|J Biomed Sci. 2025 Aug 20;32 (1) :79.|J Cell Biochem. 2023 Sep;124 (9) :1404-1422.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|J Nanobiotechnology. 2025 Jan 3;23 (1) :3.|J Oncol. 2022 Jun 23;2022:8724933.|J Pharm Anal. 2024 Aug 22.|JCI Insight. 2022 Feb 8;7 (3) :e154402.|Leuk Res. 2022 Sep:120:106920.|Mol Cancer Ther. 2024 Oct 1;23 (10) :1404-1417.|Mol Cell. 2025 Sep 4;85 (17) :3333-3342.e4.|Nat Commun. 2021 Aug 25;12 (1) :5112.|Nat Commun. 2021 Nov 16;12 (1) :6607.|Nat Commun. 2022 Aug 10;13 (1) :4689.|Nat Commun. 2025 Jan 9;16 (1) :541.|Nat Metab. 2020 Jan;2 (1) :41-49.|Nature Cancer. 2021 Apr;2 (4) :429-443.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396 (7) :1435-1450.|NPJ Precis Oncol. 2021 Mar 19;5 (1) :20.|NPJ Precis Oncol. 2025 Nov 21;9 (1) :373.|Patent. US20200108066A1|R Soc Open Sci. 2019 Jan 23;6 (1) :181714.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2022 Jul 20;12 (1) :12420.|Sci Rep. 2024 May 8;14 (1) :10582.|Sci Rep. 2019 Oct 22;9 (1) :15099. |SSRN. 2022 Nov 21.|SSRN. 2023 Sep 29.|Texas Southern University. 2024 July 02.|Transl Lung Cancer Res. 2024 May 31;13 (5) :1032-1046.|Transl Oncol. 2025 Jan 3:52:102264.|University of Gothenburg. 2023 Jun 27.|Biochem Biophys Rep. 2021 Aug 13:27:101099.|Biochem Biophys Res Commun. 2018 Sep 26;504 (1) :231-237. |Biochem Pharmacol. 2017 Jan 15:124:29-42.|Biochim Biophys Acta. 2017 Nov 20;1865 (2) :354-363.|bioRxiv. 2020 Jun.|bioRxiv. 2025 Mar 17:2025.03.14.643359.|bioRxiv. 2025 Nov 3:2025.11.02.685764.|Cancer Res. 2016 Nov 15;76 (22) :6723-6734. |Cancer Res. 2023 Oct 2;83 (19) :3264-3283.|Cell Death Dis. 2019 Mar 20;10 (4) :271.|Cell Rep. 2017 Oct 31;21 (5) :1386-1398.|Cell Rep. 2022 Sep 13;40 (11) :111331.|Cell. 2018 Nov 1;175 (4) :984-997.e24.|Clin Cancer Res. 2024 May 8.|EMBO J. 2022 Mar 15;41 (6) :e108946.|Harvard Medical School LINCS LIBRARY|J Exp Clin Cancer Res. 2022 Apr 21;41 (1) :149.|J Oncol. 2019 Jun 2;2019:5952836. |Mol Cancer Ther. 2025 Jul 2.|Mol Cell. 2017 Oct 19;68 (2) :336-349.e6.|Mol Oncol. 2017 Aug;11 (8) :1035-1049.|Nat Commun. 2017 Jun 27;8:15916.|Nat Commun. 2019 Jun 28;10 (1) :2860.|Nature. 2017 Aug 24;548 (7668) :471-475. |Nutrition. 2019 Apr:60:217-226.|Oncotarget. 2017 Jul 27;8 (56) :95116-95134. |Oncotarget. 2017 Jun 27;8 (40) :67422-67438. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|STAR Protocols. 2020 Jun 3;1 (1) :100024.

• CAS Number :

  [1231929-97-7]